Efficacy and safety of darolutamide in Black/African-American patients from the phase III ARAMIS study.
Sign Up to like & getrecommendations! Published in 2023 at "Future oncology"
DOI: 10.2217/fon-2022-0943
Abstract: Aim: Darolutamide significantly improved metastasis-free survival (MFS) and overall survival (OS) versus placebo in the phase III ARAMIS study. We evaluated outcomes in Black/African-American patients in ARAMIS. Materials & methods: Patients with nonmetastatic castration-resistant prostate… read more here.
Keywords: black african; safety; iii aramis; american patients ... See more keywords